THE DEAL, AT A GLANCE
From the announcementLyell Immunopharma
01Who is involvedBacked by Various (IPO)From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02What happenedLyell Immunopharma raised $425M IPOFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03Why it mattersLyell Immunopharma is using IPO capital to advance next-generation T cell therapy for solid tumors, a setting where the source states CAR-T fails.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Lyell Immunopharma · Financing Record
Explore source-linked visual explanations for Lyell Immunopharma. Unsupported claims are withheld while source review continues.
Record 799 · Recorded date: Needs review
What it does
Unsupported business claims are withheld pending source review. Explore the linked records for available evidence.
Explore company records →